Shares Magazine
59.00p+2.00 (+3.51%)24 Dec 2024, 10:23
Jump to:
Tissue Regenix Group PLC Fundamentals
| Company Name | Tissue Regenix Group PLC | Last Updated | 2024-12-24 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 71.235 m | Market Cap | £42.03 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.2321 | Debt Equity Ratio | 0.3278 |
| Asset Equity Ratio | 1.5378 | Cash Equity Ratio | 0.1180 |
| Quick Ratio | 1.4375 | Current Ratio | 3.74 |
| Price To Book Value | 1.7535 | ROCE | 0 |
Tissue Regenix Group PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Tissue Regenix Group PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $9.02 m | $8.94 m | $9.10 m |
| Intangible Assets | $15.13 m | $15.06 m | $15.06 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $24.15 m | $24.00 m | $24.16 m |
| Stocks | $10.36 m | $10.88 m | $9.72 m |
| Debtors | $3.68 m | $4.78 m | $4.02 m |
| Cash & Equivalents | $4.65 m | $5.95 m | $7.71 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $43.24 m | $46.04 m | $46.22 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $4.74 m | $6.64 m | $4.36 m |
| Creditors after 1 year | $9.15 m | $8.99 m | $8.47 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $13.89 m | $15.64 m | $12.83 m |
| Net assets | $29.36 m | $30.40 m | $33.39 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $91,000.00 | $9.17 m | $9.16 m |
| Share Premium | $134.25 m | $134.18 m | $134.17 m |
| Profit / Loss | -$1.67 m | -$2.83 m | -$5.14 m |
| Other Equity | $30.15 m | $31.25 m | $34.34 m |
| Preference & Minorities | -$795,000.00 | -$851,000.00 | -$950,000.00 |
| Total Capital Employed | $29.36 m | $30.40 m | $33.39 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.22 | $0.21 | $0.19 |
| Debt-to-Equity | $0.29 | $0.27 | $0.23 |
| Assets / Equity | 1.5378 | 1.5378 | 1.5378 |
| Cash / Equity | 0.1180 | 0.1180 | 0.1180 |
| EPS | -$0.02 | -$0.04 | -$0.07 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | $1.04 m | -$1.29 m | -$2.98 m |
| Cashflow before financing | -$472,000.00 | -$384,000.00 | -$3.17 m |
| Increase in Cash | -$1.31 m | -$1.47 m | -$5.21 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $29.49 m | $24.48 m | $19.75 m |
| Cost of sales | $15.45 m | $13.22 m | $11.27 m |
| Gross Profit | $14.04 m | $11.26 m | $8.48 m |
| Operating Profit | -$394,000.00 | -$2.01 m | -$4.38 m |
| Pre-Tax profit | -$1.67 m | -$2.83 m | -$5.14 m |
Tissue Regenix Group PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Itsproduct portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States. |
| Latest Interim Date | 10 Sep 2024 |
| Latest Fiscal Year End Date | 19 Mar 2024 |
Tissue Regenix Group PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-11-12 | Dr. Trevor Michael Phillips | Non-Executive Director |
| 2013-05-13 | Mr. Alan John Aubrey | Non-Executive Director |
| 2013-02-11 | Mr. Michael Anthony Bretherton | Non-Executive Director |
| 2010-06-03 | Professor William Graham Richards, CBE | Non-Executive Director |
| 2017-01-06 | Mr. Ian David Jefferson | Executive Director,Chief Financial Officer and Co Sec |
| 2024-11-12 | Mr. Jonathan Martin Glenn | Non-Executive Director,Chairman |
| 2015-02-26 | Dr. Alison Margaret Fielding | Non-Executive Director |
| 2020-03-20 | Mr. John Andrew Walter Samuel | Executive Director,Chairman |
| 2018-04-27 | Mr. Anthony Ruben Odell | Executive Director,Chief Executive Officer |
| 2020-12-04 | Mr. Alan Jonathan Richard Miller | Non-Executive Director |
| 2008-01-31 | Mr. David Robert Norwood | Non-Executive Director |
| 2009-01-31 | Professor Stephen Graham Davies MA,DPhil,DSc,CChem,MRSC | Non-Executive Director |
| 2020-12-04 | Mr. Randeep Singh Grewal | Non-Executive Director |
| 2019-08-01 | Mr. Steven Ashley Couldwell | Executive Director,Chief Executive Officer |
| 2024-11-12 | Professor Shervanthi Homer-Vanniasinkam | Non-Executive Director |
| 2018-04-27 | Mr. Paul John Devlin | Executive Director,Group Finance Director and Company Secretary |
| 2020-11-17 | Mr. Gareth Hywel Jones | Executive Director,Interim Chief Executive Officer |
| 2024-11-12 | Mr. Daniel Ray Lee | Executive Director,Chief Executive Officer |
| 2024-11-12 | Mr. Brian Phillips | Non-Executive Director |
| 2024-11-12 | Mr. David Claiborne Cocke | Executive Director,Chief Financial Officer |
Tissue Regenix Group PLC Contact Details
| Company Name | Tissue Regenix Group PLC |
|---|---|
| Address | Unit 1 & 2, Astley Way, Swillington, Astley Lane Industrial Estate, Leeds, LS26 8XT |
| Telephone | |
| Website | https://www.tissueregenix.com |
Tissue Regenix Group PLC Advisors
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2078313113 |
| Fax | +44 2030770599 |
| Nominated Adviser | Jefferies Hoare Govett |
|---|---|
| Phone | (020) 7029 8000 |
| Fax | (020) 7029 8010 |
| Stockbroker | Jefferies Hoare Govett |
|---|---|
| Phone | +44 2070298000 |
| Fax | +44 2070298010 |
| Auditor | KPMG |
|---|---|
| Phone | +44 1132313000 |
| Fax | +44 1132313200 |
| Solicitor | DLA Piper LLP |
|---|---|
| Phone | (0)8700 111 111 |
| Fax | (0) 113 369 2949 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| North Atlantic Smaller Companies Investment Trust PLC | 3,770.00 | 4.72 |
| Harworth Group PLC | 176.50 | 4.44 |
| Mobico Group PLC | 79.85 | 4.17 |
| Ithaca Energy PLC | 107.00 | 3.88 |
| Airtel Africa PLC | 112.80 | 3.87 |
| Bakkavor Group PLC | 149.50 | 3.82 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Vistry Group PLC | 547.50 | -16.28 |
| Persimmon PLC | 1,182.00 | -2.39 |
| Entain PLC | 681.40 | -1.25 |
| Firstgroup PLC | 164.40 | -1.20 |
| Jpmorgan Japanese Investment Trust PLC | 555.00 | -1.07 |
| Puretech Health PLC | 154.80 | -1.02 |
Risers/fallers data from previous trading day.